stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) Revenue growth
Penumbra, Inc.'s revenue growth over the twelve months to 30 September 2026 was 17.0%, down 0.5 percentage points from fiscal 2025 (17.5%). Over the past ten years it has ranged from 2.38% (fiscal 2020) to 48.3% (fiscal 2015); the current reading is higher than 36% of that period. That is above the Medical Devices industry median of 10.4% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 17.5% | 4.64 |
| FY2024 | 12.9% | (12.09) |
| FY2023 | 25.0% | 11.63 |
| FY2022 | 13.3% | (20.08) |
| FY2021 | 33.4% | 31.02 |
| FY2020 | 2.38% | (20.65) |
| FY2019 | 23.0% | (10.28) |
| FY2018 | 33.3% | 6.56 |
| FY2017 | 26.8% | (14.75) |
| FY2016 | 41.5% | (6.77) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 15.6% | 0.74 |
| Jun 2026 | 14.9% | (0.72) |
| Mar 2026 | 15.6% | (6.52) |
| Dec 2025 | 22.1% | 4.32 |
| 40 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| GKOS Glaukos Corporation compare | 46.9% |
| PODD Insulet Corporation compare | 26.5% |
| PEN Penumbra, Inc. | 17.0% |
| GMED Globus Medical, Inc. compare | 13.4% |
| SNN Smith & Nephew SNATS, Inc. compare | 4.81% |
| BRKR Bruker Corporation compare | 2.16% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.38% |
| BIO Bio-Rad Laboratories, Inc. compare | 1.38% |
| TXG 10x Genomics compare | −4.28% |
| Medical Devices industry median | 10.4% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on PEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement